Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 315: H7 Influenza Prime-Boost Regimens
NCT02206464Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2014
- Primary completion
- Jan 2016
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VRC-FLUDNA071-00-VP in avian influenza A H7N9 virus infection (H7N9) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Solicited adverse events (reactogenicity), Adverse events of all severities and 1 more. Started Jul 2014; status: completed.
02
Drugs
VRC-FLUDNA071-00-VP
03
Conditions
avian influenza A H7N9 virus infection (H7N9)
Beyond the preview
Go deeper on NCT02206464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206464.